Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02324010




Registration number
NCT02324010
Ethics application status
Date submitted
16/12/2014
Date registered
24/12/2014
Date last updated
7/07/2017

Titles & IDs
Public title
Effects of Sitagliptin on Gastric Emptying, Glycaemia and Blood Pressure in Type 2 Diabetes
Scientific title
Effects of Sitagliptin on Postprandial Glycaemia, Incretin Hormones and Blood Pressure in Type 2 Diabetes - Relationship to Gastric Emptying
Secondary ID [1] 0 0
140916
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Gastroparesis 0 0
Diabetes Mellitus 0 0
Condition category
Condition code
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Neurological 0 0 0 0
Other neurological disorders
Metabolic and Endocrine 0 0 0 0
Diabetes

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Sitagliptin
Treatment: Drugs - Placebo

Experimental: Sitaglipltin (100mg) - Active drug (sitagliptin)

Placebo comparator: Placebo (sugar pill) - Inactive drug (placebo)


Treatment: Drugs: Sitagliptin
100mg mane for 2 days

Treatment: Drugs: Placebo
Inactive drug (Placebo)
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Gastric emptying
Timepoint [1] 0 0
3 hours per gastric emptying study (i.e. 6 hours)
Secondary outcome [1] 0 0
Glycaemia
Timepoint [1] 0 0
4 hours during each gastric empty study (i.e. 8 hours)
Secondary outcome [2] 0 0
Gastrointestinal hormone release
Timepoint [2] 0 0
4 hours during each gastric empty study (i.e. 8 hours)
Secondary outcome [3] 0 0
Intragastric meal distribution
Timepoint [3] 0 0
3 hours during each gastric empty study (i.e. 6 hours)
Secondary outcome [4] 0 0
Blood pressure
Timepoint [4] 0 0
4.5 hours during each gastric empty study (i.e. 9 hours)
Secondary outcome [5] 0 0
Heart rate
Timepoint [5] 0 0
4.5 hours during each gastric empty study (i.e. 9 hours)
Secondary outcome [6] 0 0
Splanchnic blood flow
Timepoint [6] 0 0
4 hours during each gastric empty study (i.e. 8 hours)
Secondary outcome [7] 0 0
Cardiac output
Timepoint [7] 0 0
4 hours during each gastric empty study (i.e. 8 hours)
Secondary outcome [8] 0 0
Stroke volume
Timepoint [8] 0 0
4 hours during each gastric empty study (i.e. 8 hours)
Secondary outcome [9] 0 0
Appetite
Timepoint [9] 0 0
4 hours during each gastric empty study (i.e. 8 hours)

Eligibility
Key inclusion criteria
* Type 2 diabetes (World Health Organisation (WHO) criteria), managed by diet or metformin alone
* Body mass index (BMI) 20 - 40 kg/m2
* Males and females (females of reproductive potential must be using an appropriate contraceptive method)
* Glycated haemoglobin (HbA1c) = 8.5%
* Haemoglobin above the lower limit of the normal range (i.e. >135g/L for men and 115g/L for women), and ferritin above the lower limit of normal (i.e. >10mcg/L)
Minimum age
40 Years
Maximum age
80 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Subjects with gastrointestinal disease, significant upper or lower gastrointestinal symptoms, or previous gastrointestinal surgery (other than uncomplicated appendicectomy or cholecystectomy)
* Other significant illness, including epilepsy, cardiovascular or respiratory disease.
* History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy.
* Impaired renal or liver function (as assessed by calculated creatinine clearance < 50 mL/min using the Cockroft-Gault equation (27) or abnormal liver function tests (> 2 times upper limit of normal range)).
* Requirement for medication known to influence blood pressure and/or heart rate and/or gastrointestinal function, drugs with anticholinergic effects
* Alcohol consumption > 20 g per day
* Smoking > 10 cigarettes per day
* Pregnancy or lactation.
* Vegetarian
* Allergy to sitagliptin or any other 'gliptin'.
* Donation of blood within the previous 3 months
* Participation in any other research studies within the previous 3 months
* Exposure to ionising radiation for research purposes in the previous 12 months
* Inability to give informed consent

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Crossover
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/07/2015
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/01/2017
Sample size
Target
Accrual to date
Final
14
Recruitment in Australia
Recruitment state(s)
SA
Recruitment hospital [1] 0 0
University of Adelaide, Discipline of Medicine, Royal Adelaide Hospital - Adelaide
Recruitment postcode(s) [1] 0 0
5000 - Adelaide

Funding & Sponsors
Primary sponsor type
Other
Name
Royal Adelaide Hospital
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Karen L Jones, DAppSci, PhD
Address 0 0
University of Adelaide
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT02324010